Skip to main content

Danaher Value Stock - Dividend - Research Selection

Danaher

ISIN: US2358511028 , WKN: 866197

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company\'s Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. Its Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and flow cytometry products. The company offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians\' offices, reference laboratories, and other critical care settings. Its Dental segment provides consumables, equipment, and services to diagnose, treat, and prevent disease and ailments of the teeth, gums, and supporting bone. This segment offers implant systems, dental prosthetics, and associated treatment planning software; orthodontic bracket systems and lab products; endodontic systems and related consumables; restorative materials and instruments; infection prevention products; digital imaging systems and software; air and electric powered handpieces, and consumables; and treatment units. Its Environmental & Applied Solutions segment offers instrumentation, services, and disinfection systems to analyze, treat, and manage water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for packaging, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Danaher: 2027 Growth Reacceleration Should Drive Upside

2026-08-14

Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?

2026-08-14
When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioprocessing unit missed expectations, signaling continued softness in broader biopharma demand. The news hit European supplier Sartorius AG, which traded lower […]

3 Large-Cap Stocks We Find Risky

2026-08-13
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.

Integrated DNA Technologies Scientists Set New Performance Benchmark for CRISPR Off-Target Nomination

2026-08-11
CORALVILLE, Iowa, August 11, 2026--Research shows IDT's UNCOVERseq™ achieved the strongest combined sensitivity and precision among evaluated CRISPR off-target nomination methods.

Thermo Fisher (TMO) vs Danaher (DHR): Which Life Sciences Stock Looks Better Positioned?

2026-08-10
Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world’s largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE:TMO) raised guidance on broad-based demand improvement, Danaher’s […]

Here's How ABT Broadens Diagnostics Growth Base With Oncology Expansion

2026-08-07
Abbott broadens Diagnostics growth with Exact Sciences, as Cancer Diagnostics gains and resilient routine testing offset respiratory weakness.

Major Acquisition Alert: Julie A. Sawyer Montgomery Acquires $1.93M In Danaher Stock Options

2026-08-07
A noteworthy insider acquisition was disclosed on August 6, as Montgomery, Executive Vice President at Danaher (NYSE:DHR), reported the acquisition of stock options for 245,701 shares. What Happened: A Form 4 filing

Witness A Substantial Acquisition As Christopher Bouda Acquires $96K In Danaher Stock Options

2026-08-07
In a new SEC filing on August 6, it was unveiled that Bouda, VP at Danaher (NYSE:DHR), acquired stock options for 12,286 shares. What Happened: Bouda, VP at Danaher, engaged in a derivative transaction according to a

Matthew E Gugino Makes Strategic Play: Invests $654K In Danaher Stock Options

2026-08-07
A substantial acquisition of company stock options by Matthew E Gugino, EVP & Chief Financial Officer at Danaher (NYSE:DHR) was reported on August 6, based on a new SEC filing. What Happened: Gugino, EVP & Chief

Diamond Hill Small-Mid Cap Fund Q2 2026 Portfolio Review

2026-08-06
The Diamond Hill Small-Mid Cap Fund rose 9.71% in Q2 2026. Read the full analysis for details on portfolio moves and top contributors.